700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Article Open Access
Objectives Asthma is commonly occurring chronic disease with a large number of people having incomplete control of asthma. Now day’s combinations of inhaled corticosteroids and long acting β2 agonists are tried in patients not controlled with steroids and not many studies are available with these combinations. In this study we have evaluated and compared the efficacy of two commonly used combinations on the lung functions and sleep quality in persistent asthma. Methods 71 patients of moderate persistent asthma were randomized to receive two different treatments i.e. salmeterol/fluticasone and formoterol/ budesonide in an open, randomized, prospective, comparative study of which sixty patients completed the study successfully. Lung functions were measured using spirometry and quality of sleep was assessed using Pittsburgh Sleep Quality Index. Day time sleepiness was assessed by Epworth Sleep Scale. Results Salmeterol/fluticasone and formoterol/budesonide both significantly increased the forced expiratory volume in first second, forced vital capacity and peak expiratory flow rate, quality of sleep and daytime sleepiness from baseline values. Salmeterol/fluticasone was shown to improve night symptoms better than formoterol/ budesonide combinations. Conclusions Salmeterol /fluticasone and formoterol/budesonide, both caused significant improvement in lung functions, and an overall improvement in quality of sleep. However salmeterol/fluticasone was more beneficial in improving nocturnal symptoms.
To read the full article Peer-reviewed Article PDF
Author(s): Gupta MC, Jindal P, Chaudhry D
Asthma, combination therapies, inhaled corticosteroids, long acting beta2 agonists., Pharmaceutical Technology,Pharmaceutics,Asthma attack